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ABSTRACT

REBECCA GRIESEMER
Index Of Central Obesity As A Parameter To Evaluate Metabolic Syndrome For White,
Black, And Hispanic Adults In The United States

Metabolic syndrome is a cluster of disorders including central obesity, hypertension,
dyslipidemia, and hyperglycemia. Today’s metabolic syndrome definitions identify central
obesity by waist circumference (WC) measurements. A recent pilot study suggests that cutpoints derived from a waist-to-height ratio (WHtR), or Index of Central Obesity (ICO), is a
more accurate measurement of central obesity. This study compared the association between
the metabolic syndrome components and central obese parameters (ICO and WC) among the
white, black, and Hispanic adults in the United States. The subjects’ data was obtained from
the 2005-2006 National Health and Nutrition Examination Survey. ICO was highly
correlated with metabolic syndrome components among white subjects and the least
correlated in Hispanic subjects. Multivariate logistic regression analysis did not indicate that
ICO was a better parameter for metabolic syndrome than WC. Other WHtR cut-points may
be more sensitive in predicting metabolic syndrome components than the values used in this
study.

INDEX WORDS: metabolic syndrome, central obesity, Index of Central Obesity, waist-toheight ratio, waist circumference, hypertension, dyslipidemia, hyperglycemia, diabetes,
cardiovascular disease
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CHAPTER I
INTRODUCTION
The association between certain metabolic disorders and cardiovascular disease
was first recognized in the 1940’s.1 Professor Jean Vague proposed that upper body
obesity was better correlated with diabetes and cardiovascular disease than excess body
weight.2, 3 Vague used the terms “android adiposity” to describe the accumulation of fat
around the abdomen and “gynoid adiposity” to describe the accumulation of fat found in
the hips and thigh region.3 Vague studied the differences between the body fat
topographies and concluded that the obese gynoid phenotype was associated with
“mechanical complications” and the android phenotype was associated with metabolic
disturbances.
During the 1960’s, other researchers observed a relationship between obesity and
various metabolic related disorders.4 Dr. Reaven, in 1988, first described the cluster of
metabolic disorders related to insulin resistance.5, 6 Reaven referred to this constellation
of disorders as “Syndrome X”. Insulin resistance was the common denominator,
according to Reaven, and was associated with a hypertriglyceridemia, a decrease in high
density lipoprotein (HDL), and hypertension. However, Reaven omitted obesity as a
component of Syndrome X since he argued that insulin resistance could be found in nonobese individuals.5
With the advancement of imaging techniques such as computer tomography (CT),
researchers were able to accurately distinguish between distributions of fat and showed
an association between central obesity and metabolic disorders.7, 8 This new
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technology demonstrated how individuals with “normal” weight could have an unhealthy
accumulation of abdominal fat and develop metabolic risk factors, thus corroborating
Reaven’s finding of insulin resistance in persons with normal weight, but centrally
obesity. Since Reaven’s “Syndrome X”, the constellation of diabetes and cardiovascular
risk factors has been changed to “metabolic syndrome”, with central obesity as a required
variable of the syndrome.9-11
Although the physiopathological mechanism by which central obesity fosters
metabolic syndrome is debatable, some theories have been widely accepted.12 Visceral
fat in the truncal region is of particular importance. Compared to subcutaneous fat,
visceral fat has a higher rate of lipolysis with release of free fatty acids (FFA).12-14
Elevated levels of FFAs are known to impair insulin function and glucose uptake. FFAs
mobilized from visceral fat pass directly to the liver via the portal vein, leading to
hyperglycemia, hepatic insulin resistance, and dyslipidemia, hyperinsulinemia , and
decreased skeletal muscle insulin sensitivity.13 In contrast, the subcutaneous fat found in
the femoral-gluteal region plays a less active role in lipolysis and FFA circulation and
may be a protective factor for metabolic disorders.14 The subcutaneous fat depot acts as a
“safe haven for the sequestration of excess calories”14 and prevents FFA circulation and
fat storage in the liver, skeletal muscle and pancreas.15, 16
Currently, most health professionals agree that five components define the
metabolic syndrome: obesity, elevated triglycerides, reduced HDL, elevated blood
glucose, and hypertension.17 18, 19 However, the clinical parameters used to identify
metabolic syndrome vary among experts. For example, in 1998 the World Health
Organization (WHO) proposed that the metabolic syndrome criteria require clinical
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evidence of insulin resistance plus two of the following: (1) obese waist-to-hip ratio or
BMI >30 kg/m2, (2) raised triglycerides, (3) reduced HDL, (4) raised blood pressure, and
(5) microalbuminuria. 11, 17
In 2001, The National Cholesterol Education Program – Adult Treatment Panel
(NCEP-ATPIII) developed less stringent criteria and categorized metabolic syndrome as
having any of the following three: (1) obese waist circumference, (2) raised triglycerides,
(3) reduced HDL, (4) raised blood pressure, and (5) raised fasting blood glucose.18
Concurrently, the International Diabetes Federation (IDF) developed a metabolic
syndrome definition similar to ATPIII, with greater emphasis on central obesity. The
IDF criterion requires a diagnosis of waist circumference obesity in addition to the
presence of any two of the following: (1) raised triglycerides, (2) reduced HDL, (3) raised
blood pressure, and (4) raised fasting blood glucose. 19 In addition, the IDF recommends
using ethnic-specific obese waist circumference cut-points based on previous research
and other data sources.
Using the diagnostic guidelines, approximately 25% of adults in the United State
have been found to have metabolic syndrome--approximately 47 million American men
and women. 20, 21 Those with metabolic syndrome are at a 2-fold increased risk for
cardiovascular disease (CVD) and a 4-fold increase risk for diabetes.21-23 The metabolic
syndrome thus amplifies the public health significance of diabetes, which already affects
nearly 20.6 million U.S adults, 20 years of age and older.24 The American Diabetes
Association estimates that the 2007 medical expenditures and indirect costs for diabetes
were $174 billion.

3

In subjects with diabetes, 65% have been found to have CVD,25 also a major
health burden in the United states. An estimated 80.7 million people in the United States
had CVD in 2005 and over 860,000 deaths occurred in the prior year.26 CVD is the
leading cause of death for white, black, and Hispanic American adults, according the
American Heart Association (AHA). AHA projects the 2008 direct and indirect costs of
managing patients with CVD will be $448.5 billion. Thus, diabetes, CVD and metabolic
syndrome are overlapping conditions that contribute significantly to morbidity and
mortality in the U.S.
Measuring central obesity is a key factor in the diagnosis and surveillance of
metabolic syndrome. Various techniques such as hydrodensitometry weighing, skinfold
measurements, dual energy X-ray absorptiometry (DEXA), magnetic resonance imaging
(MRI), and CT, have been used to measure obesity, but are not necessarily appropriate
for population-based screening of central obesity.27-30 The cost, discomfort, and risk of
these methods can be prohibitive, or at a minimum, variable and operator-dependent.
Anthropometric indices, such as BMI, waist circumference (WC), waist-to-hip ratio
(WHR), and waist-to-height ratio (WHtR),31, 32 are easier to conduct and can be used as
surrogate measurements for visceral adiposity.30, 33
Although anthropometric indices of BMI, WC, WHR, and WHtR are currently
accepted measurements of obesity, experts are not in accord with which obesity indicator
is the best predictor for metabolic risk factors.17-19, 31 As previously stated, WHO uses
WHR and both NCEP-ATPIII and IDF use WC as parameters of central obesity. WHO
and IDF use BMI as an alternate obesity index when WC is not obtainable. Although,
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WHtR is not currently used as a criterion for metabolic syndrome, recent studies suggest
that WHtR may be a better parameter of central obesity.34-36
To illustrate the WHtR, a 2006 pilot study using the IDF guidelines compared two
males with identical WC and BMI measurements but of different heights.37 Their
glucose test results were considerably different, which the authors inferred could be
related to a difference in their heights. As part of their study, the researchers created a
new measurement called the Index of Central Obesity (ICO). They defined ICO as an
obese WHtR cutoff value derived from dividing the national average height by IDF’s
ethnic and gender-specific obese waist circumference values. The researchers
demonstrated that adiposity distribution may be more accurately measured with height as
part of the equation. The authors suggest that ICO may be a better measure of central
obesity than WC because it encompasses the variation of different statures.
To our knowledge, no studies have been conducted using specific WHtR cutoff
values to evaluate metabolic syndrome in the adult population in the United States. This
study hypothesizes that the novel parameter, ICO, may be better associated with
metabolic syndrome components in the white, black, and Hispanic adults in the United
States compared to WC, regardless of age or gender. This study will examine the
relationships between ICO and factors related to metabolic syndrome using adults 20
years of age and older from a large nationwide, population-based survey.
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CHAPTER II
LITERATURE REVIEW
The aim of this study is to determine if ICO is a better index of central obesity for
the diagnosis of metabolic syndrome as compared to the current WC. The discussion and
evaluation of any relationship between ICO and metabolic syndrome components would
be premature without a comprehensive literature review of the current guidelines and
central obesity indices. The literature review will include: (1) an overview of the current
guidelines for metabolic syndrome diagnosis and their rationale, (2) a review of studies
analyzing the most common central obesity parameters (BMI, WHR, WC, and WHtR),
and (3) a summary of the pilot study and their novel parameter, ICO.

2.1 Guidelines for Metabolic Syndrome
Attempts to create a unified definition of metabolic syndrome have been made by
various expert groups.33, 38 The first attempt began in 1998 as WHO responded to the
epidemic of obesity, diabetes, and cardiovascular disease and developed a preliminary set
of guidelines to assist in the diagnosis of metabolic syndrome (Table 1).33, 39 However,
some experts disagree on components of the criteria. First, measuring insulin resistance
requires specific laboratory techniques to determine if the individual is in the lowest
quartile of insulin sensitivity which may be unrealistic in certain settings.33 Second, the
criterion for high blood pressure is ambiguous. It is uncertain if the parameter for
hypertension diagnosis is ≥130mmHg systolic and ≥85mmHg diastolic or if it is
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≥130mmHg systolic or ≥85mmHg diastolic.38 Third, WHO designated WHR as a
parameter of central obesity which some argue is not be the best indicator of abdominal
adiposity.40
In 1999, the European Group for the Study of Insulin Resistance (EGIR)
developed a definition of metabolic syndrome to be used in non-diabetic subjects only,38
followed by the NCEP ATPIII’s less fastidious definition, which allows for a simple
application in clinical and epidemiological settings (Table 1).18, 38 The NCEP ATPIII
definition received criticism for their vague hypertension parameters, similar to WHO’s
parameters.38 Furthermore, the WC values are gender-specific but do not factor
racial/ethnic differences despite earlier studies demonstrating racial/ethnic disparities in
anthropometric measurements and adiposity distribution.41-49 For example, Zhu et al.
found that BMI levels corresponded to a 5 to 6 centimeter larger WC in white males
compared to black males, with Hispanic males in between.41 Other studies have
supporting evidence that blacks tend to have lower volumes of visceral adiposity and
higher volumes of subcutaneous fat at any given obesity indices compare to their white
counterparts.43-49
For the above reason, IDF developed a new definition for metabolic syndrome
that was very similar to NCEP ATPIII, but stratified WC cut-points by ethnicity (Table
1). IDF’s objective was to create one definition as a diagnostic tool applicable worldwide
for identifying patients at elevated risk of CVD or Type 2 diabetes.19, 33 Creating a
universal definition would also allow comparisons of metabolic syndrome prevalence and
surveillance across all populations. What distinguishes IDF’s definition of metabolic
syndrome from NCEP ATPIII’s is the requirement of a central obesity based on ethnic-
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specific WC cut-off values.18, 33 The IDF’s rationale for ethnic-specific WC cut-points is
based on the findings from previous cross-sectional studies identifying individuals with
elevated adiposity and elevated risk for CVD at a BMI ≥25 kg/m2 or WHR ≥0.90.33 The
IDF recommends ethnic-specific WC cut-points should be used irrespective of the
individual’s place of residence. However, the IDF recognizes that United States residents
will likely continue to be screened according to the NCED ATPIII WC cut-points: 102cm
for male and 88cm for female.
Table 1. Definitions of Metabolic Syndrome
National Cholesterol
Education Program Adult
Treatment Panel III

International Diabetes Federation

World Health Organization

Criteria

≥ 3 components

Central obesity
+ ≥ 2 components

Insulin Resistance*
+ ≥ 2 components

Obesity

WC >40” (men)
WC >35” (women)

Ethnic-specific WC values**
or BMI >30kg/m2

WHR >0.9 (men)
WHR >0.85 (women)
or BMI >30kg/m2

Triglycerides

≥150 mg/dL

≥150 mg/dL
≥150 mg/dL
or treatment for hypertriglyceridemia

HDL

<40 mg/dL (men)
<50 mg/dL (women)

<40 mg/dL (men)
<50 mg/dL (women)
or treatment for low HDL

<35 mg/dL (men)
<40 mg/dL (women)

Blood Pressure

≥ 130/85 mmHg

≥ 130mmHg systolic
or ≥85mmHg diastolic
or treament for hypertension

≥ 140/90 mmHg
or treament for hypertension

Fasting Glucose

≥ 110 mg/dL

≥ 100 mg/dL
or diagnosis of
Type II diabetes

N/A

Microalbuminuria

N/A

N/A

urniary albumin >20mg/mL or
albumin/creatinine ratio >30 mg/g

*Insulin resistance includes glucose intolerance, impaired glucose intolerance, or diabetes
**Europids, Sub-Saharan Africans, Eastern Mediterranean, Middle East (men ≥ 94cm, women ≥ 80cm); South Asian, Chinese, Japanese (men ≥ 90cm, women ≥
80cm); USA subjects will use the ATPIII values (men ≥ 102cm, women ≥88).
Sources: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf , http://www.americanheart.org/presenter.jhtml?identifier=4756 ,
http://www.idf.org/webdata/docs/MetS_def_update2006.pdf , http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf

2.2 Studies of Central Obesity Parameters
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Although specific obesity parameters are not congruent among the different
definitions of metabolic syndrome, experts concur on other metabolic syndrome
components: obesity, insulin resistance, dyslipidemia, and hypertension. As shown in
Table 1, the metabolic syndrome component of central obesity is identified by
anthropometric parameters: BMI, WHR, or WC. Currently, some researchers have
proposed another measurement, WHtR, is a more accurate measurement of central
obesity for diabetes and CVD risk assessment.34-36, 50-53
Before 1980, gender-specific weight-height tables were used to identify obese
individuals.54 These weight standards changed during 1980-1990 owing to increasing
rates of obesity and obesity-related diseases. Based on descriptive statistics of obesity
distribution and health outcomes, the United States Department of Health and Human
Services and WHO reported that BMI, weight (kg) divided by height2 (m), was a better
predictor of body adiposity and a stronger estimator of relative risk for morbidity and
mortality factors compared to weight-height.54 The National Heart, Lung, and Blood
Institute suggested that a BMI of ≥30 be used to identify individuals as obese.55
Although BMI is a useful estimator of obesity prevalence for large population
studies, this obesity index has some limitations when estimating risk of CVD and
metabolic disorders.54 The measurement of body weight does not describe the
distribution of body adiposity; weight does not discriminate lean body mass from excess
body fat. For instance, an athletic person can appear overweight or obese because of
excess muscle mass. On the other hand, an older person can appear normal weight due to
a decrease in muscle mass from influences of aging. Numerous studies have
demonstrated that BMI does not estimate central obesity and metabolic related disease as
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well as other anthropometric measurements, such as WHR, WC, and WHtR.32, 34, 35, 50, 5661

Compared to total body fat indicators, central obesity is considered a better surrogate

measurement of visceral adiposity, which is a risk factor for insulin resistance .12, 62
WHR is another commonly used central obese index. The WHR, a measurement
of the waist circumference divided by the hip circumference, is recommended by WHO
during metabolic syndrome screening. 17 The larger the ratio, the greater the tendency
towards the higher risk android adiposity; the smaller the ratio, the greater the tendency
towards gynoid adiposity. To describe the lower risk observed in gynoid phenotypes,
experts hypothesize larger hip circumferences contain subcutaneous fat that acts as a
sponge on circulating FFA.12, 14, 62 In theory, this mechanism protect the liver and
skeletal muscle from high levels of FFA and decreases the potential harmful affect on
glucose uptake and insulin production. However, the WHR can be misleading with
respect to how adiposity is distributed.2 The hip circumference could mask the
accumulation of abdominal adiposity if the hip circumference increases as well, as shown
in Figure 1. In addition, the hip circumference does not differentiate between lean body
mass and adiposity and therefore, may not accurately account for the inverse correlation
between subcutaneous fat and insulin resistance.40 Studies have demonstrated that WC
and WHtR are better predictors of central obesity, more accurate proxies of visceral
adiposity, and have stronger associations to metabolic syndrome components than
WHR.32, 53, 63
Figure 1. Misleading estimation of abdominal adiposity by WHR
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Source: Després J, Lemieux, I, Prud'homme, D. Treatment of obesity: need to focus on high risk
abdominally obese patients. British Medical Journal. 2001;322:716–720.

Waist circumference is currently the designated indicator for central obesity in
metabolic syndrome according to the two most common set of criterion: NCEP ATPIII
and IDF guidelines.58 Both expert groups use identical WC parameters to identify obese
adults in the United States: ≥102cm (40 inches) for men and ≥88cm (35 inches) for
women.18, 19 IDF requires diagnosis of central obesity diagnosis to meet the definition of
metabolic syndrome definition while NCEP ATPIII suggest individuals may be insulin
resistant without being classified as centrally obese. IDF also recommends using ethnicspecific WC cut-points for diagnosis and statistical analysis, stemming from evidence of
differences of intra-abdominal adiposity among racial/ethnic groups.19, 44
Although research has shown WC to be a robust measurement of central obesity
and metabolic disorders,30, 64 some investigators believe height in conjunction with WC is
better correlated with visceral adiposity and metabolic risk.32, 34, 35, 56 Ashwell and
colleagues accurately measured 47 individuals’ visceral adiposity via DEXA and found
the WHtR was the anthropometric index most highly correlated with intra-abdominal fat
compared to WC, BMI, and WHR (r = 0.83, 0.75, 0.69, and 0.54, respectively).51
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Other studies comparing noninvasive anthropometric measurements have shown
WHtR to be the strongest index associated with these metabolic disorders and CVD.32, 50,
56

Hsieh et al. investigated 8,278 Japanese men and women of various age groups and

assessed which index of central obesity identified subjects at a higher metabolic risk.50
Based on previous Asian studies, researchers used a WHtR cut-point of ≥0.50 and found
that individuals who were considered “normal” weight by BMI standards but centrally
obese were at a statistically significant elevated risk for metabolic disorders. In addition,
researchers reported decreases in BMI and increases in WHtR as age increased. The
authors suggest obesity may be distorted by BMI due to muscle loss, while WHtR may be
more representative of adiposity accumulation as age increases. Furthermore, female-tomale ratios of WHtR obesity index were closest to 1 across all age groups compared to
BMI and WC, implying that the WHtR 0.50 cut-point was effective for both genders.
Hence, the researchers concluded that a single WHtR may be a better parameter to
identify metabolic risks across all age groups in both genders.50
A study conducted by Gracey and colleagues evaluated the WHtR, WC, and BMI
indices as predictors of CVD in Australian Aborigines.56 They found that obesity cutpoints set at a WHtR ≥ 0.50 and a WC ≥90cm for men and ≥80cm for women were
slightly better at discriminating for diabetes or CVD compared to BMI ≥22kg/m2.
However, the authors favored a WHtR parameter as opposed to WC, asserting that a
single cut-point would allow easier implementation of public health strategies to decrease
central obesity in both males and females.56
Using receiver-operating characteristic (ROC) analysis of classifiers, Schneider
and colleagues demonstrated that an obese WHtR cut-off point between 0.54 and 0.59,
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was the most sensitive index to predict metabolic syndrome, dyslipidemia, and Type 2
diabetes in German males and females, in all age groups, compared to WHR, hip
circumference, WC, and BMI (0.70, 0.63, 0.63, 0.66, respectively).32 The higher WHtR
cut-point in the German study population (0.54-0.59) compared to other study
populations (0.50) may be a reflection of the ethnic differences emphasized by the IDF
regarding WC cut-points. Accordingly, a recent pilot study attempted to create a WHtR
parameter that would factor in the ethnic variations of waist circumferences and stature.37

2.3 ICO Pilot Study
Parikh et al. in a pilot study (discussed previously) designed a new central obesity
parameter, ICO, with the intention of determining why individuals within a certain ethnic
group, with identical waist circumferences, have dissimilar risk for metabolic disorders.37
“The ethnic difference that has led us to lower [WC] cutoffs may be essentially attributed
to differences in average height”.37 Parikh and colleagues proposed measurement, ICO,
uses a WHtR derived from the national average height divided by IDF’s WC cut-points.
The authors hypothesized that ICO correlated better with central obesity than WC, and
designed an observational study on two individuals of the same ethnic group with the
same WC.37 Shown in Figure 2, the two subjects’ body compositions are visually
different with respect to height and girth. However, their WC and BMI measurements
were identical, while their ICO, total body fat, and truncal fat measurements varied
considerably, as reported in Table 2. In addition, Subject A had normal glucose levels
while Subject B had hyperglycemia levels of 134 mg/dl. The authors concluded that their
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stature variance, accounted for by ICO, influenced the difference in their adiposity
distribution and glucose tolerance.37
Figure 2. Subject A (left),
Subject B (right)

Table 2. Comparison of two subjects in the ICO
pilot study
Parameter

Subject A

Subject B

28.8

28.8

98

98

ICO

0.557

0.645

Total Body Fat (kg)

26.2

15.8

Truncal Fat (kg)

9.5

7.4

TF in TBF (%)

36.11

46.31

BMI (kg/m2)
WC (cm)

BMI = Bmody Mass Index; WC = Waist Circumference; ICO
Index of Central Obesity; TF = Truncal Fat; TBF = Total
Body Fat

Source: Reprinted from Medical Hypotheses, 68, Rakesh M, Shashank R, Padmavathy S, and Nalini S,
Index of Central Obesity – A Novel Parameter, 1272-1275, 2007, with permission from Elsevier

2.4 Summary
The literature demonstrates that WHtR may be a better parameter for identifying
those at an elevated risk for metabolic disorders compared to WC, BMI, or WHR.
Proponents for the WHtR emphasize the simplicity of using a single WHtR value to
diagnose central obese individuals irrespective of age or gender. The WHtR cut-points of
ICO were used in these studies as proposed by expert organizations and/or from ROC
analysis. The discriminating factor between the WHtR evaluated in previous studies and
the ICO evaluated in the pilot study is that the ICO assumes the average national height
will account for ethnic differences and measure central obesity more accurately. Based
on the literature, this study will analyze the relationship between ICO and metabolic
syndrome components in white, black, and Hispanic adults in the United States.
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CHAPTER III
METHODS AND PROCEDURES

3.1 Study Purpose
This cross-sectional study was designed to: (1) determine if the Index of Central
Obesity has a stronger association with metabolic syndrome components compared to
waist circumference among the white, black, and Hispanic adults in the United States; (2)
determine race/ethnic specific differences with respect to the association between ICO
and the metabolic syndrome components; and (3) assess if the relationship between ICO
and metabolic syndrome components and varies by age.

3.2 Data Source
The data that was used in the study were obtained from the National Center for
Health Statistics’ (NCHS) National Health and Nutrition Examination Survey
(NHANES). The NCHS was created in 1960 following Congress’ National Health
Survey Act of 1956, which required the collection of information to monitor illness and
disabilities of the United States civilian non-institutionalized population. The
nationwide, population-based survey collects data via interviews, clinical tests,
measurements, and physical examinations.
From 1960 to 1970, the National Health Examination Surveys (NHES I, II, and
III) were limited to specific age groups and certain illnesses. For example, NHES I was
centered on chronic disease and adults 18-79 years of age, while NHES II and NHES III
were centered on growth and development of children 6-11 years of age and 12-17 years
of age, respectively. Stemming from the 1967 Senate hearings on Hunger in America, a
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nutrition component was added to the survey due to links between dietary intake and
disease. Starting in 1971, the name of the survey was changed to the National Health and
Nutrition Examination Survey (NHANES). By 1999, NHANES evolved into a
continuous annual survey of all ages to allow pertinent programmatic changes to
accommodate emerging public health needs.
This study used data from the NHANES 2005-2006 interviews and examinations.
The NHANES 2005-2006 survey design was a stratified, multistage probability sample
made to represent the general US population. The multiple sample stages included: (1)
selection of counties or small groups of counties, (2) block or group of blocks within
those counties, (3) households within those blocks, and (4) one or more participants
within those households. The 2005-2006 survey used higher sampling rates for lowincome persons, persons 60+ years of age, African Americans, and Mexican Americans
to increase the reliability and accuracy of statistical analysis for these groups.
During NHANES in-home interview portion, eligible participants signed consent
forms and interviewers administered health questionnaires. Computer-Assisted Personal
Interview technology was used to record participants’ answers to the demographic,
socioeconomic, dietary, and health-related questions. The health examination portion
was conducted in Mobile Examination Centers (MECs) by professional medical teams.
The examination collected health and nutrition information from physical exams, dietary
interviews, and laboratory tests. In total, the NCHS surveyed 10,348 individuals of all
ages between January 2005 and December 2006.
After the interview and examination data were collected and processed, The
Centers for Disease Control and Prevention (CDC) posted the results in a publicly
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accessible SAS transport file format on their website
(http://www.cdc.gov/nchs/nhanes.htm). All information collected from the NHANES
2005-2006 for this study was secondary, de-identified data and downloaded into SPSS®
15.0. For our research purposes, population delimitations were established to include
only white, black, and Hispanic American adults, 20 years of age and older, with waist
and height measurements documented. Of the 10,348 subjects in NHANES 2005-2006,
only 1,919 female and 1,777 males met the criteria for this study.

3.3 Study Variables
(3.3.a.) Demographic Variables
Demographic/socioeconomic variables included in this study were age, gender,
race/ethnicity, education, income, and insurance. Age was recoded into categories, of
young, middle, and older age groups (AGEGP: 1 = 20 to 39 years of age, 2 = 40 to 59
years of age, 3 = 60 or older). Analysis was stratified by gender (1 = male, 2 = female)
due to differences in obesity parameters and clinical parameters between the sexes.
Race/ethnicity was recoded as “1” for Non-Hispanic White, “2” for Non-Hispanic Black,
and “3” for Mexican American and other Hispanic. Other variables that were used in this
study include education (EDU: 1 = less than high school, 2 = high school degree or GED,
3 = more than a high school education), annual household income (INC: 1 = $0-$19,999,
2 = $20,000-$44,999, 3 = $45,000-$74,999, 4 = $75,000 or more), health insurance
coverage (INS: 1 = yes, 0 = no), and Medicare or Medicaid coverage (GOVINS: 1 = yes,
0 = no).
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(3.3.b.) Anthropometric Variables
Anthropometric measurements necessary to identify obese versus non-obese
subjects included height, weight, and waist circumference. During the NHANES
physical examination, standing height (HT) was determined at the maximum vertical size
measured in centimeters via a fixed stadiometer with a vertical backboard and moveable
headboard.65 Waist circumference (WC) was measured in centimeters from the horizontal
line above the uppermost lateral border of the right ilium.65 To capture those with
abdominal obesity, WC was transformed into an obese waist circumference variable
(MS_ObeseWC). MS_ObeseWC was coded as “1” indicating obesity if males measured
at least 102cm or if females measured at least 88cm, in accordance with IDF guidelines.19
Subjects who did not have an obese waistline were coded as “0”. Waist-to-Height Ratio
(WHtR) was computed by dividing the WC by the HT. To classify those with central
obesity, an ICO status variable (MS_ObeseICO) was created by using parameters that
were used in a previous pilot study.37 Similar to the pilot study, the ICO parameters were
computed by taking NHANES 2005-2006 average height of the American male adult,
176cm, and the American female adult, 162cm, divided by the IDF obese WC gender
cutoffs (≥102cm for men, ≥88cm for women). MS_ObeseICO was coded as “1” if the
WHtR was at or above the cutoff of 0.58 for men and 0.54 for women. Those with
WHtR’s below these values were not considered obese and were coded as “0”. BMI
(Obese_BMI), was calculated as weight(kg)/height2 (m) and coded as obese if values
were at or above 30.

(3.3.c.) Behavioral Variables
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Variables used to describe behavioral characteristics were cigarette smoking, alcohol
use, and physical activity. “Cigarette Smoker” was defined as someone who self reported
smoking 100 or more cigarettes in their lifetime. “Alcohol Use” was defined as the
average weekly alcohol consumption, derived from the subjects’ responses to drinking
questions. Average weekly alcohol consumption was calculated by multiplying the
number of days a subject drinks (per week, month, or year), by the average number of
drinks during those days, by the unit of time (52 weeks or 12 months or 1 year), and
dividing by 52 weeks. “Physical Activity” was determined using the number of times
subjects self-reported specific physical activities at a moderate or vigorous level in the
past 30 days. Physical activities included: aerobics, baseball, basketball, bicycling,
bowling, dance, fishing, football, gardening, golf, hiking, hockey, hunting, jogging,
kayaking, push-ups, racquetball, rollerblading, rowing, running, sit-ups, skating, skiing
cross country, skiing downhill, soccer, softball, stair climbing, stretching, swimming,
tennis, treadmill, volleyball, walking, weight lifting, yard work, boxing, frisbee,
horseback riding, martial arts, wrestling, yoga, cheerleading/gymnastics, rope jumping,
skateboarding, surfing, trampoline jumping, and other.

(3.3.d.) Medical History Variables
Medical history included variables of both individual and family history of diabetes,
heart disease, and stroke. Subjects who were previously diagnosed with diabetes or a
stroke were coded as having a history of diabetes or a history of a stroke respectively.
Subjects who were previously diagnosed with coronary heart disease, angina, or heart
attack were coded as having a history of heart disease. The presence of family history
included an occurrence of diabetes or heart attack in a close biological family member.
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(3.3.e.) Clinical Variables
Clinical variables essential to metabolic syndrome components included systolic and
diastolic blood pressure, serum triglyceride, HDL levels, and fasting blood glucose. For
this study, the IDF definition and cutoffs for metabolic syndrome components were used
with some exception. Systolic and diastolic blood pressure readings were administered
one to four times during the examination. The raised blood pressure variable
(MS_HighHBP) was an average of both the systolic and diastolic blood pressure
readings. If the systolic average was ≥135mmHg or the diastolic average was ≥85mmHg
or the subject reported taking hypertension medication, they were coded as having raised
blood pressure. Individuals with triglyceride levels ≥150mg/dL were categorized as
having raised triglycerides (MS_HighTri). However, subjects on a cholesterol medicine
regimen were not regarded as having raised triglycerides due to lack of information
concerning the cholesterol type targeted. Subjects with HDL levels below 40mg/dL for
men and 50mg/dL for women were defined as having abnormal reduced HDL
(MS_LowHDL). The same omission of those on a cholesterol medicine regimen applied
with this metabolic syndrome component. Individuals with fasting blood glucose levels
recorded as ≥100mg/dL or previously diagnosed diabetes were identified as having raised
fasting blood glucose (MS_HighGlucose).

3.4 Statistical Analysis
All statistical analysis was conducted using SPSS® 15.0. Tables and figures were
created using both SPSS® 15.0 and Microsoft® Office Excel 2003. All analysis was
gender specific due to gender differences in body composition and blood lipid profile.
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Characteristics of study populations were evaluated using demographic variables
(age, education level, income level, insurance status, Medicaid/Medicare status),
behavioral factors (cigarette smoking history, alcohol use, physical activity), medical
history (personal history of diabetes, heart disease, stroke; family history of diabetes,
heart attack), anthropometric measurements (waist circumference, height, waist-to-height
ratio, obese waist circumference, obese ICO, and obese BMI), and clinical measurements
(raised blood pressure, raised triglycerides, reduced HDL, raised fasting blood glucose).
For both males and females, characteristics were analyzed in three different formats: (1)
differences between racial/ethnic subgroups, (2) differences between obese and not obese
subgroups, and (3) differences between racial/ethnic subgroups of the obese study
population. Differences of continuous variables among the subgroups were tested at the
0.05 significance level using one-way analysis of variance (ANOVA) in racial/ethnic
group stratification (white, black, Hispanic) and independent t-tests in ICO status
stratification (obese/not obese). Results were reported in terms of means and standard
deviations (µ ± SD). Differences between categorical variables among the subgroups
were tested at the 0.05 significance level using chi-square and reported as a proportion of
the study population.
To evaluate the strength of the relationship between the independent variable
(ICO) and the dependent variables (metabolic syndrome components), correlation
analyses were performed. To measure the strength of association between ICO and
metabolic syndrome components among races/ethnicities, a two-tailed partial correlation
test using Pearson’s correlation analyses were conducted controlling for age. To evaluate
the strength of relationship between the same independent and dependent variables with
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respect to age, a two-tailed bivariate correlation analyses was performed using
Spearman’s Rho correlation coefficient in each age group (20-39, 40-59, 60+) stratified
by race/ethnic group. Correlations that were statistically significant were noted at both
the 0.01 level and the 0.05 level of probability.
Odds ratios (OR) were calculated at the 95% confidence level to quantify the
association of central obesity and with each metabolic syndrome component. Univariate
and multivariate logistic regression were performed to determine association between
dependent and independent variables. The OR for whites, blacks, and Hispanics was
calculated. In the multivariate regression analyses, statistical adjustments were made for
age, education level, income level, health insurance status, history of cigarette smoking,
alcohol use, and physical activity. In both univariate and multivariate analysis, WC and
ICO were analyzed separately as the independent variable to allow estimations of OR
differences. The 95% confidence level was used to determine statistical significance.
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CHAPTER IV
RESULTS

4.1 Basic Characteristics
The basic demographic factors, anthropometric measurements, behavioral factors,
medical history, and clinical factors of the eligible males and females are shown in Table
3 and Table 4 respectively. White, black, and Hispanic subjects were statistically
different with respect to age, education level, income level, insurance status, and
Medicare/Medicaid status. Hispanic men and women were younger, had a lower
education level, and had the highest uninsured rates compared to their white and black
counterparts (p<0.01). White males and females tended to be older and at a higher
socioeconomic status than their black and Hispanic counterparts (p<0.01).
Except for male BMI, all anthropometric measurements were statistically
different between white, black, and Hispanic subjects. Among males, whites had larger
waists (mean, 103cm) and higher rates of abdominal obesity (50%) than blacks and
Hispanics (p<0.05). Among females, blacks had larger waist measurements (mean,
100cm) and higher rates of abdominal obesity (73%) compared to whites and Hispanics
(p<0.001). In both men and women, Hispanics had the shortest stature among the
races/ethnicities (p<0.01).
Racial/ethnic differences were evident with respect to the history of heart disease
among males and the history of diabetes and family history of diabetes among males and
females (p<0.05). Compared to white subjects, blacks and Hispanics were twice as likely
to have diabetes (p<0.001). Within the male population, whites were at least 1.5 times
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more likely to have a history of heart disease among the three races/ethnicities (p<0.05).
Racial/ethnic differences in all other medical history were not statistical significant.
Racial/ethnic differences in rates of metabolic syndrome components (raised
blood pressure, raised triglycerides, reduced HDL, and raised fasting blood glucose) were
statistically significantly at the 0.01 level of probability with exception to glucose levels
within male subjects (p=0.08). Raised blood pressure was more prevalent in blacks and
affected 51% of black males and 47% of black females (p<0.001). Dyslipidemia and
hyperglycemia were more common in Hispanics compared to whites and blacks. In
males, Hispanics were approximately 2.2 times more likely to have raised triglycerides
and 2.3 times more likely to have reduced HDL levels than black males (p<0.001). In
females, Hispanics were 1.5 times more likely to have raised fasting blood glucose than
whites, and 2.3 times more likely to have raised triglycerides and 1.6 times more likely to
have reduced HDL than blacks (p<0.001).
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Table 3. Characteristics of the Male Study Population by Race,
NHANES 2005-2006
White
Black
Hispanic
(n = 1078)
(n = 460)
(n = 239)
Age (years)1

53 ± 19

48 ± 17

47 ± 18

<.001

< high school

17.1%

29.1%

42.3%

<.001

high school

26.3%

27.6%

17.2%

> high school

56.7%

43.3%

40.6%

<$20,000

16.9%

18.8%

17.0%

$20,000-$44,999

28.6%

34.3%

38.3%

$45,000-$74,999

24.3%

23.6%

24.3%

> $75,000

30.2%

23.3%

20.4%

Covered by Insurance

84.7%

77.2%

74.9%

<.001

Covered by Medicare/Medicaid

34.8%

25.0%

23.0%

<.001

62.4%

53.7%

51.5%

<.001

6 ± 11

4±9

5±8

0.003

11 ± 15

13 ± 16

15 ± 28

0.017

History of Diabetes

7.7%

15.9%

15.7%

<.001

History of Heart Disease

12.4%

8.9%

6.7%

0.012

History of Stroke

4.1%

4.6%

3.3%

0.742

Family History of Diabetes

34.1%

47.8%

51.1%

<.001

Family History of Heart Attack

15.8%

12.1%

11.5%

0.074

102.7 ± 15.0

100.0 ± 16.9

101.1 ± 14.3

0.005

176.5 ± 7.2

177.2 ± 7.4

171.4 ± 7.0

<.001

0.58 ± .09

0.56 ± .09

0.59 ± .08

<.001

49.9%

43.3%

42.3%

0.015

48.6%

40.7%

49.4%

0.011

31.6%

37.8%

33.1%

0.062

43.7%

50.7%

32.6%

<.001

42.3%

24.8%

54.4%

<.001

23.7%

13.1%

30.3%

<.001

29.4%

31.7%

36.8%

0.075

Medical
History

Behavioral
Factors

Demographic
Factors

Education:

Income:

2

History of Smoking
Alcohol Use

3
4

Physical Activity

1

Anthropometric
Measurements

Waist Circumference (cm)
1

Height (cm)
WtHR

1, 5

Obese Waist Circumference

6

Obese ICO7
Obese BMI

Clinical
Measurements

p-value*

8

Raised Blood Pressure

6

6

Raised Triglycerides
6

Reduced HDL

6

Raised Fasting Blood Glucose

0.008

* p-values for continuous variables and categorical variables are from oneway ANOVA and chi-square, respectively; (1) µ ± SD; (2)
Smoked at least 100 cigarettes in lifetime; (3) Average number of alcohol drinks consumed per week, (4) Number of moderate or
vigourous activites performed in the past 30 days; (5) Waist-to-Height Ratio = waist circumference (cm) / height (cm); (6) Metabolic
Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl),
reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥102 cm);
(7) Index of Central Obesity for men = waist circumference cutoff / average national height > 0.58; (8) Obese Body Mass Index (BMI) >
30
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Medical
History

Behavioral
Factors

Demographic
Factors

Table 4. Characteristics of the Female Study Population by Race,
NHANES 2005-2006
White
Black
Hispanic
(n = 1120)
(n = 503)
(n = 296)
Age (years)1

50 ± 20

46 ± 17

44 ± 17

<.001

Education: < high school

13.2%

25.8%

33.4%

<.001

high school

26.3%

19.9%

27.4%

> high school

60.5%

54.3%

39.2%

<$20,000

17.6%

27.7%

24.3%

$20,000-$44,999

27.3%

30.2%

35.1%

$45,000-$74,999

25.3%

24.0%

20.3%

> $75,000

29.8%

18.2%

20.3%

Covered by Insurance

89.6%

82.9%

81.0%

<.001

Covered by Medicare/Medicaid

31.6%

31.4%

22.0%

0.004

47.7%

33.5%

33.8%

<.001

2±4

2±9

1±2

0.036

12 ± 17

13 ± 14

12 ± 13

0.929

History of Diabetes

7.1%

13.1%

14.5%

<.001

History of Heart Disease

6.2%

6.4%

3.0%

0.094

History of Stroke

3.7%

4.0%

3.0%

0.792

Family History of Diabetes

38.6%

55.5%

57.7%

<.001

Family History of Heart Attack

17.1%

12.6%

14.1%

0.061

94.9 ± 16.1

99.8 ± 17.4

96.1 ± 14.4

<.001

162.8 ± 6.7

162.4 ± 6.5

158.2 ± 6.5

<.001

0.58 ± 0.10

0.61 ± 0.11

0.61 ± 0.10

<.001

63.5%

73.2%

69.6%

<.001

64.5%

72.0%

76.0%

<.001

32.4%

53.7%

40.9%

<.001

36.1%

47.1%

25.7%

<.001

39.1%

17.6%

41.3%

<.001

24.0%

21.7%

35.8%

<.001

18.8%

25.4%

28.4%

<.001

Income:

2

History of Smoking
3

Alcohol Use

4

Physical Activity

1

Anthropometric
Measurements

Waist Circumference (cm)
1

Height (cm)
WtHR

1, 5
6

Obese Waist Circumference
7

Obese ICO

Obese BMI
Clinical
Measurements

p-value*

8

Raised Blood Pressure

6

6

Raised Triglycerides
6

Reduced HDL

6

Raised Fasting Blood Glucose

<.001

* p-values for continuous variables and categorical variables are from oneway ANOVA and chi-square, respectively; (1) µ ± SD; (2)
Smoked at least 100 cigarettes in lifetime; (3) Average number of alcohol drinks consumed per week, (4) Number of moderate or vigourous
activites performed in the past 30 days; (5) Waist-to-Height Ratio = waist circumference (cm) / height (cm); (6) Metabolic Syndrome
Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL
(<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥88 cm); (7) Index of
Central Obesity for women = waist circumference cutoff / average national height > 0.54; (8) Obese Body Mass Index (BMI) > 30
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Age-specific (young adults, middle-aged adults, and older adults) prevalence of
ICO in the eligible men and women are shown in Figure 3 and Figures 4, respectively. A
shown, a positive linear relationship is evident: as age increases, the proportion of ICO
cases increases. Figure 3 shows the prevalence of ICO increases nearly 50% as age
increases from the youngest to the oldest group of the obese males. Figure 4 shows a
smaller increase (25%) of ICO prevalence between the youngest and oldest group of
obese females. Although the increase is not as substantial in the females, young female
adults are twice as likely to be obese as compared to their male counterparts.
Figure 3. Index of Central Obesity > 0.58 in Adult Males by Age Group,
NHANES 2005-2006
70.0%

P<0.05

59.2%

60.0%

50.0%

47.7%

40.0%

31.3%
30.0%

20.0%

10.0%

0.0%
20-39

40-59
Age Group
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60+

Figure 4. Index of Central Obesity > 0.54 in Adult Females by Age Group,
NHANES 2005-2006
90.0%
P<0.05

78.3%

80.0%

67.8%

70.0%
60.6%
60.0%

50.0%

40.0%

30.0%

20.0%

10.0%

0.0%
20-39

40-59

60+
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In Figure 5 and Figure 6, comparison of the rate of ICO in white, black, and
Hispanics in the males and females are shown respectively. In men, no differences in
obesity rates were observed in white and Hispanic, while black men presented with
approximately 10% smaller rates of ICO compared to white and Hispanic men. In
women, significant different rates of ICO are apparent with white females having fewer
subjects with ICO. Irrespective of race/ethnicity, obesity was more prevalent across
white, black, and Hispanic females (over 60%) versus the males (under 50%).
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Figure 5. Rate of ICO of White, Black, and Hispanic Men,
NHANES 2005-2006
80.0%

70.0%
P<0.05

60.0%

50.0%

49.4%

48.6%
40.7%

40.0%

30.0%

20.0%

10.0%

0.0%
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Black

Hispanic

Race/Ethnic Group

90.0%

Figure 6. Rate of ICO of White, Black, and Hispanic Women,
NHANES 2005-2006
P<0.05
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To further delineate differences between obese and non-obese subjects, the study
population was stratified by ICO parameters defined by a WHtR at or above 0.58 for
males and 0.54 for females. Differences in characteristics between the male obese (47%)
and non-obese (53%) subjects are shown in Table 5 and the female obese (68%) and nonobese (32%) subjects are shown in Table 6. With exception of income in males, obese
and non-obese subjects differed with respect to all demographic variables that were
studied (p<0.05). The obese subjects tended to be older, less educated, and more likely to
have health insurance.
As expected, anthropometric measurements varied between obese and non-obese
subjects (p<0.001). In males, 91% of obese males had an obese waist circumference
(>102), averaging 23cm larger than non-obese males. In females, 94% had an obese
waist circumference (>88cm) and were an average 25cm larger than the non-obese. A
smaller proportion of ICO obese subjects were considered BMI obese: 67% of central
obese males and 57% of central obese females had BMI >30.
Fewer non-obese subjects reported a history of diabetes, heart disease, stroke,
family history of diabetes, and family history of heart attacks compared to obese subjects
(p<0.05). Obese males and females were approximately 3 times more likely to have a
history of diabetes, 2 times more likely to have a history of heart disease, and 3 times
more likely to have a history of stroke than their non-obese counterparts (p<0.001). As
anticipated, obese subjects demonstrated higher rates of metabolic syndrome
components. In males, obese subjects were nearly 2 times more likely to have raised
blood pressure, raised triglycerides, reduced HDL, or raised fasting blood glucose in
relation to non-obese subjects (p <0.001). In females, obese subjects were approximately
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2 times more likely to have either raised blood pressure or reduced HDLS and
approximately 3 times more likely to have raised triglycerides or raised fasting blood
glucose compared to non-obese subjects (p<0.001).
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Table 5. Characteristics of the Male Study Population
1
by Index of Central Obesity (ICO) , NHANES 2005-2006

Not Obese
(n = 948)

Obese
(n = 829)

p-value*

47 ± 19

56 ± 17

<.001

< high school

22.0%

25.3%

0.021

high school

23.8%

27.1%

> high school

54.1%

47.5%

<$20,000

17.0%

17.8%

$20,000-$44,999

30.8%

32.1%

$45,000-$74,999

24.3%

23.8%

> $75,000

27.9%

26.2%

Covered by Insurance

77.4%

86.0%

<.001

Covered by Medicare/Medicaid

23.4%

39.0%

<.001

58.1%

59.3%

0.317

6 ± 12

4±9

<.001

11 ± 18

13 ± 16

0.159

History of Diabetes

6.1%

16.5%

<.001

History of Heart Disease

6.5%

15.6%

<.001

History of Stroke

2.1%

6.4%

<.001

Family History of Diabetes

34.3%

46.5%

<.001

Family History of Heart Attack

12.5%

16.3%

0.015

Waist Circumference2 (cm)

91 ± 9

114 ± 12

<.001

177 ± 7

175 ± 8

<.001

0.51 ± .05

0.65 ± .06

<.001

8.8%

91.1%

<.001

3.9%

67.2%

<.001

32.7%

56.9%

<.001

28.7%

51.5%

<.001

15.6%

28.9%

<.001

23.2%

39.9%

<.001

2

Age (years)

Clinical
Measurements

Anthropometric
Measurements

Medical
History

Behavioral
Factors

Demographic
Factors

Education:

Income:

3

History of Smoking
Alcohol Use

4
5

Physical Activity

2

Height (cm)
WtHR

2, 6

Obese Waist Circumference

7

Obese BMI 8
Raised Blood Pressure
Raised Triglycerides

7

7

7

Reduced HDL

7

Raised Fasting Blood Glucose

0.832

* p-values for continuous variables and categorical variables are from independent t-test and chi-square, respectively;
(1) ICO Status = obese (> 0.58) or not obese (< 0.58); (2) µ ± SD; (3) Smoked at least 100 cigarettes in lifetime; (4)
Average number of alcohol drinks consumed per week; (5) Number of moderate or vigourous activites performed in
the past 30 days; (6) Waist-to-Height Ratio = waist circumference (cm) / height (cm); (7) Metabolic Syndrome
Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides
(≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese
waist circumference (≥102 cm); (8) Obese Body Mass Index (BMI) > 30
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Table 6. Characteristics of the Female Study Population
1
by Index of Central Obesity (ICO) , NHANES 2005-2006

Not Obese
(n = 610)

Obese
(n = 1309)

p-value*

43 ± 18

50 ± 19

<.001

< high school

13.5%

22.5%

<.001

high school

20.9%

26.6%

> high school

65.7%

50.9%

<$20,000

18.2%

22.7%

$20,000-$44,999

23.6%

31.8%

$45,000-$74,999

21.9%

25.3%

> $75,000

36.3%

20.2%

Covered by Insurance

84.4%

87.5%

0.038

Covered by Medicare/Medicaid

20.2%

34.7%

<.001

43.7%

40.9%

0.140

3±8

2±4

<.001

12 ± 15

13 ± 16

0.469

History of Diabetes

3.6%

12.7%

<.001

History of Heart Disease

3.1%

7.0%

<.001

History of Stroke

1.5%

4.7%

<.001

Family History of Diabetes

37.2%

50.1%

<.001

Family History of Heart Attack

12.2%

17.0%

0.004

Waist Circumference2 (cm)

79 ± 6

104 ± 13

<.001

163 ± 7

161 ± 7

<.001

0.49 ± .04

0.65 ± .08

<.001

8.5%

94.2%

<.001

0.5%

57.4%

<.001

22.6%

44.2%

<.001

14.1%

43.1%

<.001

13.1%

30.8%

<.001

10.0%

27.6%

<.001

Age (years)2

Clinical
Measurements

Anthropometric
Measurements

Medical
History

Behavioral
Factors

Demographic
Factors

Education:

Income:

3

History of Smoking
4

Alcohol Use

5

Physical Activity

2

Height (cm)
WtHR

2, 6
7

Obese Waist Circumference
Obese BMI

8
7

Raised Blood Pressure
Raised Triglycerides

7

7

Reduced HDL

7

Raised Fasting Blood Glucose

<.001

* p-values for continuous variables and categorical variables are from independent t-test and chi-square, respectively; (1)
ICO Status = obese (> 0.54) or not obese (< 0.54); (2) µ ± SD; (3) Smoked at least 100 cigarettes in lifetime; (4)
Average number of alcohol drinks consumed per week; (5) Number of moderate or vigourous activites performed in the
past 30 days; (6) Waist-to-Height Ratio = waist circumference (cm) / height (cm); (7) Metabolic Syndrome Components
for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl),
reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist
circumference (≥88 cm); (8) Obese Body Mass Index (BMI) > 30
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To define racial/ethnic variations among the obese study population, the same
descriptive variables were stratified by white, black, and Hispanics. Table 7 and Table 8
show the basic description of the 829 obese males (63% white, 23% black, 14%
Hispanic) and the 1309 obese females (55% whites, 28% blacks, 17% Hispanics) in that
order. A majority of studied characteristics were significantly different between the three
obese subgroups. The average physical activity, rate of heart disease, rate of stroke,
family history of heart attacks, and rate of hyperglycemia did not vary between white,
black, and Hispanic obese subjects (p>0.05). In addition, income and WHtR did not vary
among the males while alcohol use did not vary among the females (p>0.05).
White, black, and Hispanic obese subjects were statistically different with respect
to demographic factors. On stratifying for ICO, white subjects remained older, more
educated, and more likely to have health insurance among all three races/ethnicities
(p<0.01) Hispanic subjects remained younger, with the least education, and least likely
to have health insurance (p<0.01).
Body composition differences were significant between the white, black, and
Hispanic obese subjects (p<0.05) with exception to the males’ WHtR. Among the three
subgroups, obese black subjects were inclined to have larger anthropometric
measurements while obese Hispanic subjects tended to be smaller in stature and waist
measurements. In addition, variation in central obesity prevalence depended on the type
of indicator. For example, 20% of Hispanic males with an obese ICO were not obese
according to WC measurements compared to only 5% of black males.
Racial/ethnic differences among the obese subjects were observed in the history
of diabetes, history of heart disease, and family history of diabetes (p <0.05). Among the
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three races/ethnicities, heart disease was most prevalent in obese white males and females
while diabetes was most prevalent in obese black males and obese Hispanic females. The
rate of metabolic syndrome components, with exception to blood glucose levels, varied
between the obese white, black, and Hispanic (p<0.001) as well. Obese black subjects
had higher rates of raised blood pressure while obese Hispanic subjects had higher rates
of raised triglycerides and reduced HDL levels.
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Table 7. Characteristics of the Obese Male Study Population by Race,
ICO > 0.58, NHANES 2005-2006
White
Black
Hispanic
p-value*
(n = 524)
(n = 187)
(n = 118)
Age (years)1

58 ± 17

51 ± 17

50 ± 17

<.001

< high school

19.8%

27.8%

45.8%

<.001

high school

27.5%

31.0%

19.5%

> high school

52.7%

41.2%

34.7%

<$20,000

17.5%

18.7%

17.9%

$20,000-$44,999

29.8%

35.2%

37.5%

$45,000-$74,999

23.9%

22.0%

26.8%

> $75,000

28.8%

24.2%

17.9%

Covered by Insurance

89.7%

81.3%

77.1%

<.001

Covered by Medicare/Medicaid

43.1%

32.1%

31.4%

0.005

63.9%

50.3%

53.4%

0.002

5 ± 10

3±6

3±6

0.036

Physical Activity

12 ± 17

14 ± 15

13 ± 12

0.630

History of Diabetes

12.9%

23.9%

20.9%

0.001

History of Heart Disease

17.7%

13.9%

8.5%

0.033

History of Stroke

5.5%

9.6%

5.1%

0.120

Family History of Diabetes

42.0%

56.4%

50.4%

0.003

Family History of Heart Attack

18.0%

13.8%

13.0%

0.255

114 ± 12

115 ± 12

111 ± 12

0.003

175 ± 7

177 ± 8

170 ± 7

<.001

0.65 ± 0.06

0.66 ± 0.06

0.65 ± 0.07

0.829

92.2%

95.2%

79.7%

<.001

62.6%

81.8%

64.4%

<.001

57.8%

65.8%

39.0%

<.001

54.0%

34.4%

67.3%

<.001

29.9%

17.8%

42.1%

<.001

38.5%

41.7%

43.2%

0.550

Clinical
M easurements

Anthropom etric
M easurem ents

M edical
History

Behavioral
Factors

Dem ographic
Factors

Education:

Income:

2

History of Smoking
3

Alcohol Use

4

Waist Circumference1 (cm)
1

Height (cm)
WtHR

1, 5
6

Obese Waist Circumference
Obese BMI

7
6

Raised Blood Pressure
Raised Triglycerides

6

6

Reduced HDL

Raised Fasting Blood Glucose

6

0.259

* p-values for continuous variables and categorical variables are from oneway ANOVA and chi-square, respectively; (1) µ ± SD; (2)
Smoked at least 100 cigarettes in lifetime; (3) Average number of alcohol drinks consumed per week, (4) Number of moderate or
vigourous activites performed in the past 30 days; (5) Waist-to-Height Ratio = waist circumference (cm) / height (cm); (6) Metabolic
Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl),
reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥102 cm);
(7) Obese Body Mass Index (BMI) > 30
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M edical
History

Behavioral
Factors

Demographic
Factors

Table 8. Characteristics of the Obese Female Study Population by Race,
ICO > 0.54, NHANES 2005-2006
White
Black
Hispanic
p-value*
(n = 722)
(n = 362)
(n = 225)
Age (years)1

52 ± 20

48 ± 17

45 ± 17

<.001

Education: < high school

15.5%

27.3%

37.3%

<.001

high school

29.1%

20.7%

28.0%

> high school

55.4%

51.9%

34.7%

<$20,000

19.0%

28.4%

25.2%

$20,000-$44,999

30.5%

31.6%

36.7%

$45,000-$74,999

27.0%

24.1%

21.4%

> $75,000

23.5%

15.8%

16.7%

Covered by Insurance

92.1%

83.4%

79.5%

<.001

Covered by Medicare/Medicaid

37.7%

35.1%

24.4%

0.001

History of Smoking

47.2%

33.1%

33.3%

<.001

Alcohol Use3

2±4

1±5

1±3

0.092

Physical Activity

13 ± 18

13 ± 15

12 ± 12

0.757

History of Diabetes

10.0%

14.4%

18.6%

0.002

History of Heart Disease

8.2%

6.9%

3.1%

0.033

History of Stroke

5.1%

4.4%

3.6%

0.602

Family History of Diabetes

43.4%

58.2%

58.6%

<.001

Family History of Heart Attack

18.7%

14.2%

15.7%

0.162

104 ± 13

107 ± 14

101 ± 12

<.001

162 ± 7

162 ± 6

158 ± 6

<.001

0.64 ± .08

0.66 ± .09

0.64 ± .08

<.001

94.0%

96.7%

90.7%

0.010

50.0%

74.3%

53.8%

<.001

44.6%

53.6%

28.0%

<.001

51.9%

21.4%

48.4%

<.001

30.4%

25.7%

39.8%

0.002

25.3%

29.6%

31.6%

0.117

Income:

2

4

Clinical
M easurements

Anthropom etric
M easurements

1

Waist Circumference (cm)
1

Height (cm)
WtHR

1, 5
6

Obese Waist Circumference
Obese BMI

7
6

Raised Blood Pressure
6

Raised Triglycerides
6

Reduced HDL

6

Raised Fasting Blood Glucose

0.001

* p-values for continuous variables and categorical variables are from oneway ANOVA and chi-square, respectively; (1) µ ± SD; (2)
Smoked at least 100 cigarettes in lifetime; (3) Average number of alcohol drinks consumed per week, (4) Number of moderate or vigourous
activites performed in the past 30 days; (5) Waist-to-Height Ratio = waist circumference (cm) / height (cm); (6) Metabolic Syndrome
Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL
(<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥88 cm); (7) Obese Body
Mass Index (BMI) > 30
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4.2 Correlation Between Central Obesity Indicators & Metabolic Syndrome
Components
The degree of linear correlation between ICO and four metabolic syndrome
components was assessed in males and females. The results of the correlation analysis
between ICO and metabolic syndrome components, stratified by race/ethnicity and
adjusted for age, are shown in Table 9 (males) and Table 10 (females). Raised blood
pressure and raised fasting blood glucose were positively correlated with ICO among all
three races/ethnicities, but not significant in Hispanic subjects (p>0.05). Raised
triglycerides and reduced HDL were positively associated with ICO and significant in all
three racial/ethnic groups (p <.05). In males, an ICO in whites, blacks, and Hispanics had
a higher degree of correlation with raised triglycerides, raised blood pressure, and
reduced HDL, respectively. The ICO of obese white, black, and Hispanic females had a
higher degree of correlation with raised triglycerides, reduced HDL, and raised
triglycerides, in that order.
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Table 9. Correlation with ICO1 and Metabolic Syndrome Components2,
Age-Adjusted, Obese Male Study Population, NHANES 2005-2006
Metabolic Syndrome
Components

White
(n = 524)

Black
(n = 187)

Hispanic
(n = 460)

Raised Blood Pressure2

.196**

.214**

.052

Raised Fasting Blood Glucose2

.147**

.143**

.089

Raised Triglycerides2

.251**

.183**

.234**

Reduced HDL2

.172**

.127**

.253**

Significance of association was measured using a two-tailed, partial correlation while controlling for age.
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
(1) Index of Central Obesity for men = waist circumference cutoff / average national height > 0.58
(2) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking
meds), raised triglycerides (≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or
Type II diabetes diagnosis), obese waist circumference (≥102 cm)

Table 10. Correlation with ICO1 and Metabolic Syndrome Components2,
Age-Adjusted, Obese Female Study Population, NHANES 2005-2006
Metabolic Syndrome
Components

White
(n = 722)

Black
(n = 362)

Hispanic
(n = 225)

Raised Blood Pressure2

.180**

.115*

.015

Raised Fasting Blood Glucose2

.196**

.123**

.059

Raised Triglycerides2

.352**

.138**

.246**

Reduced HDL2

.213**

.169**

.140*

Significance of association was measured using a two-tailed, partial correlation while controlling for age.
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
(1) Index of Central Obesity for women = waist circumference cutoff / average national height > 0.54
(2) Metabolic Syndrome Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking
meds), raised triglycerides (≥150mg/dl), reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or
Type II diabetes diagnosis), obese waist circumference (≥88 cm)
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Further evaluation of ICO’s relationship with the four metabolic syndrome
components was conducted to determine if age influenced the correlation. The results of
the correlation analyses, stratified by racial/ethnic groups and age groups (20-39, 40-59,
60+), are reported in Table 11 (males) and Table 12 (females). As shown, the majority of
associations between ICO and metabolic syndrome was positive and significantly
correlated (p <0.05), and most prevalent in obese white subjects and least frequent in
obese Hispanics across race/ethnic and age groups.
Among whites, blacks, and Hispanics, the degree of correlation between ICO and
each metabolic syndrome component varied with respect to age. No discernable patterns
of association with increasing age were apparent across the racial/ethnic groups with
respect to statistical significance or strength of correlation. Overall, no specific trend was
observed between ICO and metabolic syndrome components with respect to advancing
age.
Table 11. Age-Specific Correlation with ICO1 and Metabolic Syndrome Components2,
Obese Male Study Population, NHANES 2005-2006

Metabolic Syndrome
Components
2

Age 20 - 39

Age 40 - 59

Age 60+

White
Black
Hispanic
(n = 314) (n = 164) (n = 91)

White
Black
Hispanic
(n = 340) (n = 148) (n = 70)

White
Black
Hispanic
(n = 424) (n = 148) (n = 78)

.212**

.220**

.164

.242**

.146

Raised Fasting Blood Glucose

.078

.195*

.194

.231**

.043

Raised Triglycerides2

.293**

.121

.313**

.232**

Reduced HDL2

.226**

.073

.178

.161**

Raised Blood Pressure

2

-.057

.151**

.291**

.051

.033

.082

.203*

.029

.299**

.051

.230**

.126

.374**

.097

.332**

.133**

.203*

.328**

Signficance of bivariate correlation was measured using Spearmans Rho.
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
(1) Index of Central Obesity for men = waist circumference cutoff / average national height > 0.58
(2) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL (<40
mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥102 cm)
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1

2

Table 12. Age-Specific Correlation with ICO and Metabolic Syndrome Components ,
Obese Female Study Population, NHANES 2005-2006

Metabolic Syndrome
Components

Age 20 - 39

Age 40 - 59

Age 60+

White
Black
Hispanic
(n = 408) (n = 195) (n = 136)

White
Black
Hispanic
(n = 332) (n = 180) (n = 88)

White
Black
Hispanic
(n = 380) (n = 128) (n = 72)

Raised Blood Pressure2

.078

.122

-.045

.274**

.231**

.124

.147**

Raised Fasting Blood Glucose2

.148**

.165*

.045

.210**

.087

.007

.219**

Raised Triglycerides2

.430**

.175*

.259**

.324**

.211*

.325**

.282**

-.020

Reduced HDL2

.132**

.194**

.198*

.323**

.131

.155

.194**

.200*

-.040
.071

.000
.249*
.130
-.006

Signficance of bivariate correlation was measured using Spearmans Rho.
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
(1) Index of Central Obesity for women = waist circumference cutoff / average national height > 0.54

4.3 Univariate Analysis Between Central Obesity Indicators & Metabolic Syndrome
Components
Binary logistic regression was performed to quantify the association of ICO and
WC obesity with metabolic syndrome components. Stratified by race/ethnicity, the odds
of centrally obesity and raised blood pressure, raised fasting glucose, raised triglycerides,
or reduced HDL are shown in Table 13 and Table 14 for males and females respectively.
Both WC and ICO were associated with increased odds of each metabolic syndrome
component. The odds ratios were not statistically significant in Hispanic females’ ICO
status and high blood pressure or between Hispanic males’ WC and high blood pressure
and raised blood glucose. All other odds ratios were statistically significant.
In Table 13 and Table 14, the odds ratios varied between central obesity indices
with metabolic syndrome components. In males, the majority of metabolic syndrome
components had a stronger association with ICO compared to WC, but not statistically
significant. A much stronger associations were observed in Hispanic males with all four
metabolic syndrome components, black males with hypertension or reduced HDL, and
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white males with hypertension compared to a WC >102cm. As for the females, both WC
and ICO had similar association with the metabolic syndrome components.
Although not statistically different, white subjects had the highest odds with the
majority of metabolic syndrome components. ICO parameters were associated with
highest odds for raised blood pressure and raised fasting blood glucose in the white males
while Hispanic males had the highest odds for raised triglycerides and reduced HDL.
White males with WC >102cm were the most likely to have raised blood pressure, raised
fasting blood glucose, and raised triglycerides among the races/ethnicities. White
females with an ICO >0.54 or a WC >88cm had the highest odds of having any of the
four metabolic syndrome components compared to blacks and Hispanics.
1

2

3

Table 13. Univariate Association of ICO and WC with Metabolic Syndrome Components ,
Male Study Population by Race, NHANES 2005-2006
Metabolic Syndrome Components

Male WC ≥ 102cm

Male ICO ≥ 0.58

Raised
Blood Pressure

Raised
Fasting Blood Glucose

Raised
Triglycerides

Reduced
HDL

OR

95% CI

OR

95% CI

OR

95% CI

OR

95% CI

Whites
(n = 524)

3.2

(2.5 - 4.0)

2.4

(1.8 - 3.1)

2.6

(2.0 - 3.4)

2.0

(1.5 - 2.6)

Blacks
(n = 187)

2.8

(1.9 - 4.2)

2.2

(1.4 - 3.2)

2.4

(1.5 - 3.8)

2.0

(1.1 - 3.5)

Hispanics
(n = 118)

1.8

(1.0 - 3.1)

1.7

(1.0 - 2.9)

2.9

(1.7 - 5.0)

3.2

(1.8 - 5.9)

Total
(n = 829)

2.7

(2.2 - 3.3)

2.2

(1.8 - 2.7)

2.6

(2.2 - 3.2)

2.2

(1.7 - 2.8)

Whites
(n = 538)

2.8

(2.2 - 3.5)

2.5

(1.9 - 3.2)

2.6

(2.0 - 3.3)

2.3

(1.7 - 3.0)

Blacks
(n = 199)

2.5

(1.7 - 3.6)

2.2

(1.5 - 3.4)

2.4

(1.5 - 3.8)

1.9

(1.0 - 3.3)

Hispanics
(n = 101)

1.4

(0.8 - 2.4)

1.5

(0.9 - 2.6)

2.5

(1.5 - 4.4)

2.3

(1.3 - 4.1)

Total
(n = 838)

2.4

(2.0 - 2.9)

2.2

(1.8 - 2.7)

2.5

(2.0 - 3.0)

2.2

(1.7 - 2.8)

OR and 95% CI were calculated using binary logistic regression; (1) ICO for men = waist circumference cutoff / average national height > 0.58; (2) Obese WC
for men > 102cm; (3) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides
(≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis)
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Table 14. Univariate Association of ICO1 and WC2 with Metabolic Syndrome Components3,
Female Study Population by Race, NHANES 2005-2006
Metabolic Syndrome Components

Female WC ≥ 88cm

Female ICO ≥ 0.54

Raised
Blood Pressure

Raised
Fasting Blood Glucose

Raised
Triglycerides

Reduced
HDL

OR

95% CI

OR

95% CI

OR

95% CI

OR

95% CI

Whites
(n = 722)

3.1

(2.3 - 4.1)

4.7

(3.1 - 7.1)

5.9

(4.3 - 8.1)

3.2

(2.3 - 4.5)

Blacks
(n = 362)

2.6

(1.7 - 4.0)

2.4

(1.4 - 4.0)

3.2

(1.6 - 6.4)

2.7

(1.5 - 4.8)

Hispanics
(n = 225)

1.7

(0.9 - 3.4)

2.1

(1.1 - 4.0)

4.3

(2.2 - 8.5)

2.3

(1.2 - 4.3)

Total
(n = 1309)

2.7

(2.2 - 3.4)

3.4

(2.6 - 4.6)

4.6

(3.6 - 6.0)

2.9

(2.3 - 3.9)

Whites
(n = 711)

2.9

(2.2 - 3.9)

4.9

(3.2 - 7.5)

5.7

(4.2 - 7.8)

3.0

(2.2 - 4.3)

Blacks
(n = 368)

2.7

(1.8 - 4.2)

2.2

(1.3 - 3.7)

2.1

(1.1 - 4.0)

3.0

(1.6 - 5.6)

Hispanics
(n = 206)

1.6

(0.9 - 2.9)

2.3

(1.2 - 4.2)

4.9

(2.6 - 9.1)

2.9

(1.6 - 5.4)

Total
(n = 1285)

2.7

(2.2 - 3.3)

3.4

(2.6 - 4.6)

4.3

(3.3 - 5.5)

3.0

(2.3 - 3.9)

OR and 95% CI were calculated using binary logistic regression; (1) ICO for women = waist circumference cutoff / average national height > 0.54; (2) Obese
WC for women > 88cm; (3) Metabolic Syndrome Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised
triglycerides (≥150mg/dl), reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis)

Additional analysis was conducted to determine if trends in age influenced the
association of central obesity with metabolic syndrome components. Stratified by the
three age groups (20-39, 40-59, 60+), binary logistic regression calculated the odds of
being ICO or WC obese with raised blood pressure, raised fasting glucose, raised
triglycerides, or reduced HDL, which are shown in Table 15 (males) and Table 16
(females). All odds ratios were statistically different between obese and non-obese
subjects across all age groups.
The strength of association with central obesity and metabolic syndrome
components differed across age and gender. The association tended to be higher in the
youngest subjects, 20-39 years of age, in both WC and ICO categories. In males, ICO
demonstrated higher odds in the majority of metabolic syndrome components, which may
indicate a better parameter for metabolic syndrome in males. However, in the female
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analysis, the WC appeared to be a stronger risk factor for metabolic syndrome
components than ICO in the majority of strata.
1

2

3

Table 15. Univariate Association of ICO and WC with Metabolic Syndrome Components ,
Male Study Population by Age Group, NHANES 2005-2006
Metabolic Syndrome Components

Male WC ≥ 102cm

Male ICO ≥ 0.58

Raised
Blood Pressure

Raised
Fasting Blood Glucose

Raised
Triglycerides

Reduced
HDL

OR

95% CI

OR

95% CI

OR

95% CI

OR

95% CI

Age 20 - 39
(n = 178)

2.7

1.8 - 4.1

2.2

1.4 - 3.6

2.8

1.9 - 4.1

2.3

1.5 - 3.4

Age 40 - 59
(n = 266)

2.0

1.4 - 2.8

1.9

1.3 - 2.7

2.6

1.8 - 3.6

2.4

1.6 - 3.7

Age 60+
(n = 385)

2.0

1.4 - 2.7

1.5

1.1 - 2.1

2.8

2.0 - 3.9

2.9

1.8 - 4.6

Total
(n = 829)

2.7

(2.2 - 3.3)

2.2

(1.8 - 2.7)

2.6

(2.2 - 3.2)

2.2

(1.7 - 2.8)

Age 20 - 39
(n = 189)

2.4

1.6 - 3.7

2.3

1.4 - 3.7

2.8

1.9 - 4.1

2.5

1.7 - 3.8

Age 40 - 59
(n = 274)

2.0

1.4 - 2.8

1.7

1.2 - 2.5

2.4

1.7 - 3.3

2.4

1.6 - 3.7

Age 60+
(n = 375)

1.7

1.2 - 2.4

1.7

1.3 - 2.4

2.4

1.7 - 3.3

2.4

1.5 - 3.7

Total
(n = 838)

2.4

(2.0 - 2.9)

2.2

(1.8 - 2.7)

2.5

(2.0 - 3.0)

2.2

(1.7 - 2.8)

OR and 95% CI were calculated using binary logistic regression; (1) ICO for men = waist circumference cutoff / average national height > 0.58; (2) Obese WC
for men > 102cm; (3) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides
(≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis)
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Table 16. Univariate Association of ICO1 and WC2 with Metabolic Syndrome Components3,
Female Study Population by Age Group, NHANES 2005-2006
Metabolic Syndrome Components

Female WC ≥ 88cm

Female ICO ≥ 0.54

Raised
Blood Pressure

Raised
Fasting Blood Glucose

Raised
Triglycerides

Reduced
HDL

OR

95% CI

OR

95% CI

OR

95% CI

OR

95% CI

Age 20 - 39
(n = 448)

2.2

1.0 - 4.7

4.0

1.8 - 8.5

5.7

3.7 - 8.7

2.3

1.6 - 3.4

Age 40 - 59
(n = 407)

3.1

2.1 - 4.5

2.4

1.5 - 3.8

4.7

2.9 - 7.6

4.1

2.6 - 6.6

Age 60+
(n = 454)

1.7

1.1 - 2.7

3.1

1.9 - 5.0

3.0

1.9 - 4.8

3.6

1.8 - 6.9

Total
(n = 1309)

2.7

(2.2 - 3.4)

3.4

(2.6 - 4.6)

4.6

(3.6 - 6.0)

2.9

(2.3 - 3.9)

Age 20 - 39
(n = 448)

2.2

1.0 - 4.7

5.6

2.3 - 13.2

6.5

4.2 - 10.1

2.3

1.5 - 3.4

Age 40 - 59
(n = 409)

4.2

2.8 - 6.2

2.5

1.6 - 4.0

4.1

2.6 - 6.5

3.8

2.4 - 6.1

Age 60+
(n = 428)

1.9

1.3 - 2.9

3.2

2.0 - 5.0

2.5

1.7 - 3.8

3.9

2.1 - 7.1

Total
(n = 1285)

2.7

(2.2 - 3.3)

3.4

(2.6 - 4.6)

4.3

(3.3 - 5.5)

3.0

(2.3 - 3.9)

OR and 95% CI were calculated using binary logistic regression; (1) ICO for women = waist circumference cutoff / average national height > 0.54; (2) Obese WC
for women > 88cm; (3) Metabolic Syndrome Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides
(≥150mg/dl), reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis)

4.4 Multivariate Analysis Between Central Obesity Indicators & Metabolic
Syndrome Components
To obtain a more accurate estimate of the true association of central obesity with
metabolic syndrome components, multivariate regression was conducted. These
analyses took into account several predictive variables simultaneously which controlled
for age, education level, income level, health insurance status, smoking history, alcohol
use, physical activity, and family history. The likelihood of being ICO or WC obese with
each metabolic syndrome component was stratified by white, black, and Hispanic
subjects and reported in Table 17, Table 18, and Table 19 respectively.
Shown in all three tables, most of the independent variables were not statistically
significant among the races/ethnicities in both genders. Regarding race/ethnicity, the
obese white subjects had elevated risks for each metabolic syndrome component
(p<0.05), the obese black subjects had elevated risks for each metabolic syndrome
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component but not consistently significant, and the obese Hispanic subjects had elevated
and reduced risks for metabolic syndrome components but not statistically significant in
all cases. With respect to gender, females with a WC >88cm tended to have higher odds
with metabolic syndrome components than females with an ICO >0.54, with exception to
the blacks’ glucose and triglyceride levels. Males with an ICO >0.58 consistently had
higher odds of having raised blood pressure compared to males with a WC >102cm.
However, the odds of raised blood glucose, raised triglycerides, and reduced HDL varied
between ICO and WC among the white, black, and Hispanic obese males. Overall,
central obesity based on WC classification was associated with higher odds in twice as
many strata compared to ICO.
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(0.72-1.80)
ref

1.14

ref

high school

> high school

6

(0.79-1.93)
ref

1.23

ref

high school

> high school

6

(0.99-1.01)
(0.74-1.57)

1.07

(1.00-1.04)

(0.70-1.51)

1.00

1.02

1.68

1.00

1.01

0.97

0.92

ref

1.22

1.12

1.08

ref

1.19

2.00

1.03

2.06

1.66

1.00

1.02

0.96

0.91

ref

1.25

1.10

1.07

ref

1.15

1.97

1.03

1.86

(1.14-2.48)

(0.99-1.01)

(1.00-1.03)

(0.65-1.46)

(0.49-1.70)

ref

(0.74-2.01)

(0.66-1.90)

(0.55-2.11)

ref

(0.75-1.90)

(1.11-3.61)

(1.01-1.04)

(1.40-3.05)

(1.12-2.45)

(0.99-1.01)

(1.00-1.03)

(0.64-1.44)

(0.49-1.70)

ref

(0.76-2.06)

(0.65-1.87)

(0.55-2.09)

ref

(0.72-1.83)

(1.09-3.56)

(1.02-1.04)

(1.25-2.75)

Raised
Blood Glucose
OR
95% CI

1.29

1.00

1.01

0.81

0.97

ref

1.31

1.02

1.47

ref

1.41

0.80

1.00

2.56

0.36

1.00

1.01

0.81

0.96

ref

1.36

1.00

1.48

ref

1.30

0.77

0.99

3.02

(0.90-1.83)

(0.99-1.01)

(1.00-1.03)

(0.56-1.16)

(0.57-1.64)

ref

(0.84-2.05)

(0.63-1.64)

(0.80-2.70)

ref

(0.93-2.16)

(0.43-1.46)

(0.98-1.00)

(1.77-3.70)

(0.83-1.7)

(0.98-1.01)

(1.00-1.03)

(0.56-1.17)

(0.56-1.64)

ref

(0.87-2.14)

(0.62-1.62)

(0.80-2.73)

ref

(0.86-2.03)

(0.41-1.43)

(0.98-1.00)

(2.07-4.41)

Raised
Triglycerides
OR
95% CI

1.44

0.99

0.94

0.86

1.84

ref

0.96

1.06

1.95

ref

1.78

1.13

0.97

2.40

1.39

0.99

0.94

0.85

1.87

ref

0.97

1.08

1.95

ref

1.70

1.14

0.97

2.29

(0.95-2.19)

(0.98-1.01)

(0.90-0.97)

(0.56-1.32)

(0.97-3.48)

ref

(0.56-1.65)

(0.60-1.89)

(0.98-3.87)

ref

(1.10-2.90)

(0.55-2.30)

(0.96-0.99)

(1.55-3.71)

(0.91-2.13)

(0.97-1.01)

(0.90-0.97)

(0.56-1.30)

(0.98-3.56)

ref

(0.57-1.66)

(0.61-1.91)

(0.98-3.86)

ref

(1.05-2.77)

(0.56-2.32)

(0.96-0.99)

(1.47-3.57)

Reduced
HDL
OR
95% CI

1.73

1.01

1.02

0.89

0.88

ref

0.87

0.71

0.62

ref

1.37

2.00

1.10

3.40

1.82

1.00

1.01

0.84

0.95

ref

0.93

0.83

0.67

ref

1.47

1.98

1.10

2.28

(1.07-2.80)

(0.99-1.02)

(0.96-1.09)

(0.55-1.44)

(0.37-2.09)

ref

(0.47-1.59)

(0.36-1.39)

(0.27-1.45)

ref

(0.78-2.39)

(0.80-5.03)

(1.08-1.12)

(1.96-5.89)

(1.13-2.93)

(0.99-1.02)

(0.96-1.07)

(0.52-1.44)

(0.41-2.21)

ref

(0.51-1.70)

(0.43-1.60)

(0.29-1.56)

ref

(0.85-2.54)

(0.78-5.02)

(1.08-1.12)

(1.34-3.87)

1.99

0.99

1.03

1.47

1.02

ref

0.49

0.47

0.57

ref

2.00

1.94

1.05

4.03

2.06

0.99

1.03

1.37

1.01

ref

0.53

0.53

0.58

ref

2.08

1.79

1.04

3.54

(1.16-3.42)

(0.97-1.01)

(0.96-1.10)

(0.86-2.52)

(0.36-2.89)

ref

(0.24-1.01)

(0.22-1.00)

(0.23-1.38)

ref

(1.09-3.67)

(0.77-4.89)

(1.03-1.06)

(2.00-8.11)

(1.21-3.53)

(0.97-1.01)

(0.96-1.10)

(0.80-2.35)

(0.36-2.86)

ref

(0.26-1.06)

(0.25-1.12)

(0.24-1.41)

ref

(1.14-3.81)

(0.71-4.55)

(1.03-1.06)

(1.75-7.19)

Raised
Blood Glucose
OR
95% CI

1.01

0.99

0.99

1.24

1.08

ref

1.36

1.29

2.09

ref

0.68

0.85

1.00

7.39

1.03

0.99

0.98

1.15

1.07

ref

1.47

1.45

2.10

ref

0.73

0.81

1.00

5.87

(0.69-1.48)

(0.97-1.00)

(0.93-1.04)

(0.83-1.85)

(0.54-2.13)

ref

(0.83-2.21)

(0.77-2.17)

(1.04-4.19)

ref

(0.42-1.09)

(0.40-1.82)

(0.99-1.01)

(4.63-11.80)

(0.71-1.51)

(0.97-1.00)

(0.93-1.03)

(0.78-1.70)

(0.55-2.10)

ref

(0.91-2.37)

(0.87-2.41)

(1.06-4.14)

ref

(0.45-1.16)

(0.38-1.71)

(0.99-1.01)

(3.73-9.24)

Raised
Triglycerides
OR
95% CI

1.35

1.00

0.94

1.24

0.53

ref

1.09

0.77

1.53

ref

1.16

1.70

0.99

3.22

1.36

0.99

0.94

1.19

0.52

ref

1.13

0.81

1.54

ref

1.17

1.61

0.99

3.12

(0.88-2.06)

(0.98-1.01)

(0.87-1.01)

(0.80-1.93)

(0.27-1.03)

ref

(0.63-1.86)

(0.42-1.40)

(0.74-3.16)

ref

(0.70-1.93)

(0.76-3.78)

(0.98-1.00)

(1.93-5.36)

(0.89-2.08)

(0.98-1.01)

(0.87-1.01)

(0.77-1.85)

(0.27-1.01)

ref

(0.66-1.93)

(0.44-1.47)

(0.74-3.18)

ref

(0.70-1.96)

(0.72-3.59)

(0.98-1.00)

(1.87-5.22)

Reduced
HDL
OR
95% CI

Metabolic Syndrome Components of White Females
Raised
Blood Pressure
OR
95% CI
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OR and 95% CI was calculated for Metabolic Syndrome Components using binary logistic regression while controlling for age, education, income, insurance, smoking status, alcohol use, and physical activity; (1) ICO for women = > 0.54, ICO for men = >
0.58; (2) Obese WC for women > 88cm, Obese WC for men > 102cm; (3) Metabolic Syndrome Components men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL (women <50 mg/dl,
men <40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis); (4) Smoked at least 100 cigarettes in lifetime; (5) Average number of alcohol drinks consumed per week, (6) Number of moderate or vigourous activites performed in
the past 30 days, (7) Family history of diabetes or heart attack in close biological family member.

Family History ? yes

7

Physical Activity

Alcohol Use

5

1.03

ref

ref

> $75K

4
Cigarette Smoker ? Yes

(1.02-2.61)

1.63

$45K-$74,999

(0.95-2.93)

(0.80-2.23)

1.34

$20K-$44,999

1.77

(0.83-3.06)

1.59

<$20K

Health Insurance? Yes

Income:

(0.71-2.46)

1.32

< high school

Education:

(1.03-1.06)

(1.69-3.56)

2.46

1.04

Age (years)

(0.66-1.44)

(0.99-1.01)

(1.0-1.04)

(0.70-1.52)

WC

0.98

1.00

1.02

Family History ? yes

7

Physical Activity

Alcohol Use

5

1.03

ref

ref

> $75K

4
Cigarette Smoker ? Yes

(1.06-2.75)

1.71

$45K-$74,999

(0.95-3.33)

(0.79-2.23)

1.32

$20K-$44,999

1.78

(0.83-3.12)

1.61

<$20K

Health Insurance? Yes

Income:

(0.67-2.37)

1.26

< high school

Education:

(1.03-1.05)

1.04

Age (years)

(2.12-4.56)

3.11

ICO

Raised
Blood Pressure
OR
95% CI

Metabolic Syndrome Components of White Males

Table 17. Multivariate Association of ICO1 and WC2 with Metabolic Syndrome Components3
in the White Study Population, NHANES 2005-2006

6

6

2

(0.99-1.03)
(0.59-2.10)

1.01

1.11

(0.98-1.04)

1.36

0.99

1.02

0.61

1.16

ref

1.06

0.71

1.73

ref

0.91

0.51

1.06

1.76

1.34

0.99

1.02

0.61

1.16

ref

1.04

0.69

1.65

ref

0.90

0.54

(0.73-2.54)

(0.97-1.02)

(0.98-1.05)

(0.31-1.21)

(0.50-2.72)

ref

(0.46-2.48)

(0.30-1.69)

(0.63-4.77)

ref

(0.45-1.85)

(0.19-1.42)

(1.03-1.08)

(0.95-3.25)

(0.72-2.50)

(0.97-1.02)

(0.98-1.05)

(0.31-1.20)

(0.50-2.72)

ref

(0.45-2.43)

(0.29-1.63)

(0.60-4.53)

ref

(0.45-1.83)

(0.20-1.49)

(1.03-1.08)

(0.95-3.31)

0.76

0.99

1.00

1.27

0.55

ref

0.58

0.76

0.67

ref

1.58

0.90

1.01

2.04

0.75

0.99

1.00

1.24

0.55

ref

0.57

0.72

0.62

ref

1.54

0.94

1.01

2.04

(0.40-1.47)

(0.96-1.01)

(0.96-1.04)

(0.62-2.60)

(0.24-1.28)

ref

(0.23-1.50)

(0.31-1.84)

(0.22-1.98)

ref

(0.75-3.31)

(0.32-2.57)

(0.99-1.03)

(1.05-3.93)

(0.39-1.45)

(0.96-1.01)

(0.96-1.04)

(0.61-2.53)

(0.24-1.27)

ref

(0.22-1.45)

(0.30-1.76)

(0.21-1.85)

ref

(0.73-3.24)

(0.33-2.69)

(0.98-1.03)

(1.05-3.96)

Raised
Triglycerides
OR
95% CI

0.97

0.98

0.89

1.90

2.46

ref

0.39

0.96

0.51

ref

2.97

3.35

0.97

1.47

0.97

0.98

0.89

1.90

2.57

ref

0.39

0.94

0.54

ref

2.99

3.41

0.97

1.17

(0.38-2.46)

(0.94-1.02)

(0.77-1.03)

(0.68-5.29)

(0.64-9.52)

ref

(0.09-1.65)

(0.29-3.14)

(0.12-2.76)

ref

(0.98-8.97)

(0.80-14.06)

(0.93-1.00)

(0.58-3.74)

(0.38-2.45)

(0.94-1.02)

(0.77-1.02)

(0.68-5.34)

(0.66-10.02)

ref

(0.09-1.64)

(0.29-3.09)

(0.11-2.61)

ref

(0.98-9.11)

(0.81-14.32)

(0.93-1.00)

(0.44-3.06)

Reduced
HDL
OR
95% CI

1.18

0.99

1.02

0.96

0.98

ref

0.78

2.81

2.99

ref

0.74

0.25

1.12

2.62

1.14

0.99

1.03

0.95

0.97

ref

0.81

2.95

3.10

ref

0.71

0.23

1.12
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OR and 95% CI was calculated for Metabolic Syndrome Components using binary logistic regression while controlling for age, education, income, insurance, smoking status, alcohol use, and physical activity; (1) ICO for women = > 0.54, ICO for men = >
0.58; (2) Obese WC for women > 88cm, Obese WC for men > 102cm; (3) Metabolic Syndrome Components men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL (women <50 mg/dl,
men <40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis); (4) Smoked at least 100 cigarettes in lifetime; (5) Average number of alcohol drinks consumed per week, (6) Number of moderate or vigourous activites performed in
the past 30 days, (7) Family history of diabetes or heart attack in close biological family member.
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Table 18. Multivariate Association of ICO and WC with Metabolic Syndrome Components
in the Black Study Population, NHANES 2005-2006
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OR and 95% CI was calculated for Metabolic Syndrome Components using binary logistic regression while controlling for age, education, income, insurance, smoking status, alcohol use, and physical activity; (1) ICO for women = > 0.54, ICO for men = >
0.58; (2) Obese WC for women > 88cm, Obese WC for men > 102cm; (3) Metabolic Syndrome Components men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL (women <50 mg/dl,
men <40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis); (4) Smoked at least 100 cigarettes in lifetime; (5) Average number of alcohol drinks consumed per week, (6) Number of moderate or vigourous activites performed in
the past 30 days, (7) Family history of diabetes or heart attack in close biological family member.
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Table 19. Multivariate Association of ICO and WC with Metabolic Syndrome Components
in the Hispanic Study Population, NHANES 2005-2006

CHAPTER V
DISCUSSION AND CONCLUSION

5.1 Discussion
Based on our results, we failed to reject the null hypothesis and were unable to
support ICO as a better parameter for metabolic syndrome diagnosis compared to WC
among white, black, and Hispanic adults in the United States. Our findings included: (1)
subjects with ICO or obese WC had elevated risks of raised blood pressure, raised blood
glucose, raised triglycerides, and reduced HDL, (2) the association between ICO and
each metabolic syndrome component was not significantly different from WC, (3) the
odds of having raised blood pressure, raised blood glucose, raised triglycerides, or
reduced HDL was not consistently higher in either ICO or WC and varied between
race/ethnicity and gender, (4) the correlation and association of central obesity and
metabolic syndrome components was found statistically significant more often in white
subjects compared to black and Hispanic subjects, and (5) prevalence of ICO increased as
age increased, but age did not influence the correlation and association of ICO with
metabolic syndrome components.
Differences of demographic factors, behavioral factors, and medical history were
observed in the study subpopulations, with a focus centered on the racial/ethnic and
gender disparities regarding anthropometric measurements and risk for metabolic
syndrome components. Prevalence of obesity among the racial/ethnic groups depended
on the anthropometric parameter used. Our analysis indicated 33% of men and 37 % of
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women from our study population were considered obese with a BMI ≥30. When
stratified by race/ethnicity, disparities in the prevalence of obese BMI measurements
were found in the females but not in the males. Approximately 54% of black women and
41% of Hispanic women were obese compared to 32% of white women. These results
were very similar to the 2003-2004 prevalence of obesity in the United States reported by
the Centers for Disease Control and Prevention (CDC).66 However, when our study
population was measured for central obesity by WC and WHtR parameters, the
prevalence within the groups increased, but the gap between the groups decreased
considerably among the black, Hispanic, and white females (73%, 70%, 64% and 72%,
76%, 65% respectively). While WC identified a larger proportion of centrally obese in
white and black males and females, Hispanics had the highest prevalence of central
obesity based on ICO. When stratified by ICO status, Hispanic subjects with an ICO were
more likely to have coexisting normal WC measurements compared to whites and blacks.
Other notable racial/ethnic and gender differences were observed with respect to
height measurements, waist circumference measurements, and clinical measurements.
Comparing genders, women had higher rates of obesity based on all anthropometric
measurements: BMI, WC, and ICO. However, the females had lower rates of metabolic
syndrome components (hypertension, elevated triglycerides, and elevated fasting blood
glucose), with exception to the higher rates of reduced HDL levels in black and white
obese females. The lower rates may be contributable to the protective influence of
gynoid adiposity on insulin resistance, which is common in the female phenotype.7, 12, 14,
61

When stratified by ICO status, obese females and obese males had very similar WHtR

averages ranging from 0.64 to 0.66. This may indicated that a WHtR is a closer
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agreement of parameters between genders and may adjust for sexual dimorphism.
Having a single WHtR value to measure central obesity in either gender is a plausible
concept.
Comparing race/ethnicity, Hispanics tended to be shorter than whites and blacks,
larger in girth than whites, and had higher rates of ICO than whites and blacks. A larger
proportion of Hispanics was affected by raised triglycerides, reduced HDL, and raised
fasting blood glucose compared to whites and blacks, although glucose levels were not
statistically different. The ICO appears to be encompassing the adjustment for the
smaller stature in the Hispanic population. Further analysis of univariate and multivariate
binary logistic regression indicated racial/ethnic inequalities with respect to the
association of ICO and WC parameters with metabolic syndrome components. During
univariate analysis, white subjects (particularly males) with an ICO presented higher risks
for metabolic syndrome components compared to WC. When age, education, income,
health insurance status, smoking status, alcohol use, physical activity, and family history
were controlled for, ICO and WC remained a statistical significant indicator in the white
subjects, but less significant in the black and Hispanics. These results may be a reflection
of the ICO parameters derived from previous studies and national averages, which is
heavily dominated by the white race. The United States adult population is comprised of
approximately 76% Caucasians.67 Ethnic-specific ICO cut-points may be needed for the
diverse groups in the United States.

5.2 Limitations
This study does present some limitations. Restrictions existed due to the study
design and the nature of secondary data. First, the cross-sectional design does not allow
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for temporality and direction of risk factors and health outcomes. From this design, it is
indeterminable if central obesity occurred before or after metabolic syndrome
components developed. Second, the secondary data obtained from NHANES 2005-2006
did not provide sufficient information to satisfy IDF’s definition of metabolic syndrome
components. For example, NHANES inquires “are you taking prescribed medication for
high cholesterol” but does not prompt the subject for the type of cholesterol being
treated.68 Cholesterol-reducing medications include the following categories: (1) statins
lower LDL and modestly lower triglycerides and raise HDL, (2) selective cholesterol
absorption inhibitors lower LDL and modestly lower triglycerides and raise HDL, (3)
resins lower LDL, (4) fibrates lower triglycerides and sometime increase HDL, and (5)
niacin lowers triglycerides and LDL and raises HDL.69 Since it is undetermined what
cholesterols are being affected, subjects who reported they were taking cholesterol
medication in conjunction with normal triglyceride and HDL levels were omitted as
having elevated triglycerides or reduced HDL. This may have underestimated the
prevalence of hyperlipidemia and distorted the correlation and association. Case in point,
the prevalence of male subjects with elevated triglyceride levels potentially could have
increased from 39.4% to 47.2% if subjects taking cholesterol medication were included.
And the third limitation in our study design hinders the application of our findings to the
general public. These results can not be generalized to the entire United States population
because our delimitations excluded subjects under the age 20 and races/ethnicities other
than white, black, or Hispanic.
Another limitation was in the definition of WC parameters. IDF defines central
obesity using gender and ethnic-specific WC cut-points. They acknowledge that these
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are pragmatic cut-points and that further research is required for risk assessment. Even
so, guidelines for IDF WC cut-points for the white, black, and Hispanic populations in
the United States are unclear. IDF recommends: (1) United States citizens of Europid
origin should use both European [≥94cm for men, ≥80cm for women) and North
American [≥102cm for men, ≥88cm for women] cut-points during epidemiological
studies, but comments that NCEP ATP-III cut-points will be used in clinical settings, (2)
Sub-Saharan Africans should use European data until more specific data are available, (3)
Arab populations should use European data until more specific data are available, and (4)
ethnic South and Central Americans should use South Asian recommendations [≥90cm
for men, ≥80cm for women] until more specific data are available. When referring to
European data, it was uncertain if the black Americans of Sub-Saharan and Arab descent
should use Europid cut-points or use North American cut-points. Also Hispanics were
confined to ethnic South and Central Americans. Based on the ambiguity and the
emphasis on current clinical practices in the United States, NCEP ATPIII WC cut-points
were used for white, black, and Hispanic adults study population. Ethnic-specific cutpoints for WC and ICO for this study population may have produced different results.

5.3 Recommendations for Future Research
First, future research should conduct longitudinal studies to determine which
WHtR value is most effective for screening central obesity and predicting metabolic
syndrome in white, black, and Hispanic adults of the United States. Previous studies
conducted ROC analysis to determine the WHtR value most sensitive to metabolic
syndrome components. Researchers may want to design similar studies to determine if
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other WHtR cut-points are better indicators of metabolic syndrome than the ICO
parameters used in this study. Second, researchers may want to analyze for spurious
affects with respect to the correlation of WHtR with metabolic syndrome components, as
suggested by Molarius and Seidall.70 They indicate that short stature has been associated
with increased morbidity and may create a false correlation between WHtR and health
events. Studies should address this issue and test for validity. And lastly, public health
experts should evaluate the different parameters of central obesity and determine which is
the most sensitive for detecting metabolic syndrome. A single definition of metabolic
syndrome needs to be created to best capture the risk of this disorder across all
populations.

5.4 Conclusion
Central obesity is a risk factor that can lead to insulin resistance and metabolic
syndrome. Those with metabolic syndrome have significantly higher risks for developing
diabetes or CVD. Public health experts estimate that billions of dollars in medical
expenditures and indirect costs are spent managing patients with diabetes and CVD each
year in the United States. Morbidity and mortality stemming from central obesity has
reached epidemic proportions. Implementing a central obesity parameter that can
accurately capture those at risk of developing metabolic syndrome is crucial.
Although this study failed to support the hypothesis that ICO was a better
parameter for metabolic syndrome for the white, black, and Hispanic American adults,
ICO should be considered a robust measurement for estimating central obesity and
metabolic syndrome risk in addition to WC. ICO was found to be highly correlated and
exposed adults to elevated risks for hypertension, dyslipidemia, and insulin resistance.
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Future studies may discover a more sensitive ICO cut-point value that identifies a larger
portion of individuals at elevated risks for metabolic syndrome. Nonetheless, a universal
definition of metabolic syndrome is pertinent to improve screening and surveillance of
central obesity across all populations.
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